Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 8/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14752729 | 0.89 | BCHE (0.40) | ADRB2MEN1KMT2A | |
| SCHEMBL11817531 | 0.88 | ALDH1A1 (0.42) | ADRB2TDP1ADRB1ADRB3BRD4 | |
| SCHEMBL11820069 | 0.87 | ADRB2 (0.40) | ADRB2MEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL7798917 | 0.86 | ADRB2 (0.45) | ADRB2TDP1L3MBTL1ADRB1ADRB3 | |
| SCHEMBL719851 | 0.86 | ADRB2 (0.45) | ADRB2TDP1L3MBTL1ADRB1ADRB3 | |
| SCHEMBL274550 | 0.86 | ADRB2 (0.45) | ADRB2TDP1L3MBTL1ADRB1ADRB3 | |
| SCHEMBL30341869 | 0.86 | ADRB2 (0.45) | ADRB2TDP1L3MBTL1ADRB1ADRB3 | |
| SCHEMBL3070143 | 0.86 | APP (0.40) | ADRB2MEN1KMT2AADRB1ADRB3 | |
| SCHEMBL6074837 | 0.85 | ADRB3 (0.50) | ADRB2ADRB3 | |
| SCHEMBL11819250 | 0.85 | ADRB2 (0.39) | ADRB2ADRB1ADRB3BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538127-B2 | Medicinal compounds | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| EP-1554264-B1 | MEDICINAL ARYLETHANOLAMINE COMPOUNDS | GLAXO GROUP LTD (GB) | 2007-08-08 | — | — | EP | disclosed |
| US-20060205790-A1 | Medicinal arylethanolamine compounds | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | US | disclosed |
| US-20060148771-A1 | Medicinal compounds | GLAXO GROUP LIMITED (GB) | 2006-07-06 | — | — | US | disclosed |
| EP-1592656-A2 | MEDICINAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-11-09 | — | — | EP | disclosed |
| EP-1554264-A2 | MEDICINAL ARYLETHANOLAMINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004071388-A2 | MEDICINAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2004-08-26 | — | — | WO | disclosed |
| WO-2004037807-A9 | MEDICINAL ARYLETHANOLAMINE COMPOUNDS | GLAXO GROUP LTD (GB) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004037807-A2 | MEDICINAL ARYLETHANOLAMINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148771-A1 | Medicinal compounds | AVPR1B, AVPR2, CYP11B1 | ADRB2 98/4885MEN1 22/4885KMT2A 3938/4885 |
| US-20060205790-A1 | Medicinal arylethanolamine compounds | NAT1, AADAC, AHR | ADRB2 117/4885MEN1 2806/4885KMT2A 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.